PSMA-targeted radiopharmaceuticals for prostate cancer diagnosis and therapy
JD Oldan, F Almaguel, AF Voter, A Duran… - The Cancer …, 2024 - journals.lww.com
Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume …
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer
G Santo, G Di Santo, A Sviridenko… - European Journal of …, 2024 - Springer
Background The purpose of this study was to evaluate the safety and outcome of
rechallenge [177Lu] Lu-PSMA-I&T in newly progressed mCRPC patients after response to …
rechallenge [177Lu] Lu-PSMA-I&T in newly progressed mCRPC patients after response to …
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously …
R Flippot, T Telli, M Velev, A Fléchon… - European Urology …, 2024 - Elsevier
Background Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-
PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an …
PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an …
[HTML][HTML] Predicting Response to [177Lu] Lu-PSMA Therapy in mCRPC Using Machine Learning
K Gong, B Magnier, S L'hostis, F Borrely… - Journal of Personalized …, 2024 - mdpi.com
Background/Objectives: Radioligandtherapy (RLT) with [177Lu] Lu-PSMA has been newly
introduced as a routine treatment for metastatic castration-resistant prostate cancer …
introduced as a routine treatment for metastatic castration-resistant prostate cancer …
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers
Abstract 177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic
castration-resistant (mCRPC) patients who progressed to androgen receptor pathway …
castration-resistant (mCRPC) patients who progressed to androgen receptor pathway …
[引用][C] Correlating Prostate-specific Antigen Dynamics with Outcomes of Lutetium-177-PSMA-617 Treatment: Refining Predictive and Prognostic Biomarkers
Correlating Prostate-specific Antigen Dynamics with Outcomes of Lutetium-177-PSMA-617
Treatment: Refining Predictive and Prognostic Biomarkers Correlating Prostate-specific Antigen …
Treatment: Refining Predictive and Prognostic Biomarkers Correlating Prostate-specific Antigen …